Executive Director
Viridian Therapeutics
Executive Director
Viridian Therapeutics
Develops miRNA-targeting therapies for autoimmune diseases
At Viridian, we work with a sense of urgency for patients, creating unity with our team, the industry, and the community. We are committed to using proven science and engineering to improve the lives of people living with serious and rare diseases, and we are getting closer to achieving this goal every day.
At Viridian Therapeutics, we are focused on developing best-in-class medicines for people living with autoimmune and rare diseases. Leveraging our team’s expertise in antibody discovery and engineering, we have created a robust pipeline of differentiated investigational therapeutic candidates for well-validated targets.
Reporting to the Senior Vice President, Global Regulatory Affairs, the Executive Director, International Regulatory Affairs will lead the development and execution of regulatory strategy across Europe and Rest of World (ROW) markets, translating corporate and portfolio priorities into coordinated regulatory plans that enable development and commercialization objectives.
This individual will partner with the Global Regulatory Lead on the development and execution of international regulatory strategies across all stages of product development and commercialization, ensuring alignment with corporate objectives and global regulatory requirements.
The position requires deep expertise in European regulatory procedures, extensive experience interacting with international health authorities, and demonstrated leadership in developing innovative regulatory strategies for biologics and other pharmaceutical products.
In close collaboration with cross-functional partners, the Executive Director integrates scientific, non-clinical, clinical, regulatory and business insights to guide and support the development of critical programs. The role ensures that development strategies are aligned with regulatory expectations and are designed to achieve successful outcomes in target global markets.
This role may be located in the United States or the United Kingdom. For remote employees, travel to US headquarters for meetings may be required at the discretion of management. For those local to Waltham, MA, our office-based employees are required to work in the office three (3) days a week.
Responsibilities (including, but not limited to):
Qualifications:
Viridian offers a comprehensive benefits package including:
Viridian Therapeutics, Inc. provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination, harassment, or retaliation of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by Federal, State, and Local laws. Viridian will ensure that individuals with disabilities are provided reasonable accommodation to participate in the job application or interview process, to perform essential job functions, and to receive other benefits and privileges of employment. Please contact us to request accommodation.
Viridian Therapeutics, Inc participates in E-Verify, the federal program for electronic verification of employment eligibility.
Applicant Privacy Notice: Information submitted in connection with your application will be processed in accordance with Viridian's Privacy Policy, available here.
Salary Range 257000 - 315000 USD
Develops miRNA-targeting therapies for autoimmune diseases
Viridian Therapeutics discovers and develops therapies that target microRNA (miRNA) pathways to treat autoimmune diseases, with a focus on thyroid eye disease. The company uses monoclonal antibody technology aimed at the IGF-1 receptor (IGF-1R) pathway to modulate disease biology. Its product approach integrates miRNA biology with antibody engineering to create treatments that intervene in autoimmune processes. The company differentiates itself by combining miRNA-targeting strategies with IGF-1R–focused monoclonal antibodies, operating in the clinical-stage space and concentrating on rare thyroid-related autoimmune conditions. Its goal is to advance clinical candidates through development toward regulatory approval and eventual market launch for patients who suffer from these diseases.
Explore more opportunities at Viridian Therapeutics